Alnylam Pharmaceuticals (ALNY)

Alnylam Pharma Financial Statements


Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently ―. The company's EPS TTM is $-8.165; its P/E ratio is -24.51; Alnylam Pharma is scheduled to report earnings on October 27, 2022, and the estimated EPS forecast is $-1.75. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 224.82M$ 213.26M$ 258.54M$ 187.63M$ 220.55M
Gross Profit$ 184.01M$ 177.63M$ 220.87M$ 154.97M$ 181.80M
EBIT$ -232.06M$ -196.99M$ -223.49M$ -163.96M$ -154.91M
EBITDA$ -201.51M$ -187.53M$ -202.03M$ -140.74M$ -122.49M
Net Income Common Stockholders$ -277.40M$ -240.34M$ -258.46M$ -204.51M$ -189.56M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 1.71B$ 1.83B$ 1.87B$ 1.90B$ 2.11B
Total Assets$ 3.33B$ 3.43B$ 3.64B$ 3.47B$ 3.51B
Total Debt$ 329.45M$ 516.48M$ 523.23M$ 759.19M$ 762.26M
Net Debt$ -1.38B$ -1.32B$ -1.35B$ -1.14B$ -1.35B
Total Liabilities$ 3.15B$ 3.03B$ 3.06B$ 2.72B$ 2.66B
Stockholders Equity$ 176.04M$ 401.17M$ 588.20M$ 755.89M$ 853.36M
Cash Flow
Free Cash Flow$ -138.87M$ -189.05M$ -172.03M$ -160.10M$ -133.10M
Operating Cash Flow$ -122.82M$ -171.19M$ -150.14M$ -134.04M$ -121.86M
Investing Cash Flow$ 142.79M$ -147.42M$ -413.40M$ -88.27M$ 157.02M
Financing Cash Flow$ 30.34M$ 34.96M$ 292.29M$ 573.84M$ 329.81M
Currency in USD

Alnylam Pharma Earnings and Revenue History

Alnylam Pharma Debt to Assets

Alnylam Pharma Cash Flow

Alnylam Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis